$1.53
+0.04(3.02%)
Mkt Cap $91M
$0.96
$2.90
52-Week Range
At a Glance
AI-generated8-K
Biomea Fusion, Inc. reported financial results for the full year ended December 31, 2025, with a net loss attributable to common stockholders of $61.8 million and cash, cash equivalents, and restricted cash of $56.2 million, projecting a cash runway into the first quarter of 2027. The company highlighted clinical progress including 52-week data from COVALENT-111 and initiations of COVALENT-211, COVALENT-212, and GLP-131 trials.$91M
Market Cap
—
Revenue
-$140M
Net Income
Employees79
Fundamentals
How The Business Makes Money
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001840439
ISINUS09077A1060
CUSIP09077A106
Phone650 980 9099
Address900 Middlefield Road, Redwood City, CA, 94063, US
SEC EDGAR